Benjamin Ebert

Benjamin Ebert made the landmark discovery that lenalidomide and related immunomodulatory drugs (IMiDs) function as molecular glues that redirect the cereblon E3 ubiquitin ligase to degrade the transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos), explaining their remarkable efficacy in multiple myeloma and myelodysplastic syndromes. He further showed that lenalidomide induces degradation of casein kinase 1 alpha (CK1alpha) in MDS with del(5q), providing the molecular basis for its therapeutic selectivity. His work established the molecular glue paradigm as a major drug discovery platform. His discoveries fundamentally changed understanding of how thalidomide derivatives work in cancer.